LivaNova's share price and revenue have been falling for five years, worrying investors. However, the CEO's modest pay could be a positive. The company's future growth is uncertain.
The company's low P/S, despite strong revenue growth, is tied to weaker future revenue forecasts compared to the industry, deterring investors, which hinders the P/S ratio from increasing. A rise in future revenue is needed to justify a higher P/S ratio.
With a continuous trend of declining ROCE, LivaNova's growth seems doubtful. Under competitive pressures and being a matured enterprise, suggestions lean towards considering other investment options.
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
LivaNova Stock Forum
LivaNova's Earnings Surge: How 8.7% Revenue Growth and Positive Clinical Trials Are Reshaping Its Future
watching this one around 9am
keep these on watch $LivaNova (LIVN.US)$ $1847 Holdings (EFSH.US)$ $Healthy Choice Wellness (HCWC.US)$ $Allarity Therapeutics (ALLR.US)$ $Fly-E (FLYE.US)$ $N2OFF (NITO.US)$ $Syra Health (SYRA.US)$
apextradez 👈🏻 hind us for more alerts led by the Best Alpha.Scorpio
• $Banc of California (BANC.US)$: Raymond James Upgrades to Outperform from Market Perform - PT $22
• $Cullen/Frost Bankers (CFR.US)$: Raymond James Upgrades to Outperform from Market Perform
• $W.W. Grainger (GWW.US)$: Wolfe Research Upgrades to Outperform from Peerperform
• $Invitation Homes Inc (INVH.US)$: Evercore ISI Upgrades to Outperform from In Line - PT $46 (from $44)
• $PCB Bancorp (PCB.US)$: Raymond James Upgrades to Outperform from Market Perfor...
No comment yet